Castle Biosciences (CSTL) News Today $24.94 -0.15 (-0.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Castle Biosciences to share data on DecisionDx-SCCJanuary 17 at 5:13 PM | markets.businessinsider.comDerek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the transaction, the insider now owns 80,818 shares of the company's stock, valued at approximately $2,265,328.54. This represents a 1.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.January 15, 2025 | marketbeat.comCastle Biosciences stock tumbles following guidance concernsJanuary 13, 2025 | investing.comCastle Biosciences (NASDAQ:CSTL) Trading Down 14% - Here's WhyCastle Biosciences (NASDAQ:CSTL) Shares Down 14% - Should You Sell?January 13, 2025 | marketbeat.comCastle expects FY24 revenue to meet or exceed top end of $320M-$330M guidanceJanuary 13, 2025 | msn.comCastle Biosciences Positioned for Growth After Novitas Resolution and Focus on Core FranchisesJanuary 13, 2025 | markets.businessinsider.comCastle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue GuidanceJanuary 13, 2025 | markets.businessinsider.comBarclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Barclays PLC increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 310.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,301 shares of the company's stock after purchasing an additionalJanuary 13, 2025 | marketbeat.comCastle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsJanuary 12, 2025 | businesswire.comHarbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Harbor Capital Advisors Inc. decreased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 23.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 118,500 shares of the company's stock after selling 35,407 shares durinJanuary 11, 2025 | marketbeat.comCastle Biosciences stock falls following Medicare coverage denialJanuary 10, 2025 | au.investing.comCanaccord Genuity Keeps Their Buy Rating on Castle Biosciences (CSTL)January 10, 2025 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Castle Biosciences (CSTL)January 10, 2025 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) Shares Gap Down - Time to Sell?Castle Biosciences (NASDAQ:CSTL) Shares Gap Down - Here's What HappenedJanuary 10, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,715 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $29.62, for a total value of $80,418.30. Following the transaction, the insider now owns 82,047 shares in the company, valued at $2,430,232.14. This represents a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 8, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the sale, the director now owns 1,425 shares of the company's stock, valued at $41,524.50. The trade was a 84.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.January 8, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Up 6.2% - Time to Buy?Castle Biosciences (NASDAQ:CSTL) Trading Up 6.2% - Still a Buy?January 7, 2025 | marketbeat.comCastle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus TestJanuary 6, 2025 | finance.yahoo.comCastle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus TestJanuary 6, 2025 | businesswire.comBeyond The Numbers: 7 Analysts Discuss Castle Biosciences StockJanuary 2, 2025 | benzinga.comCastle Biosciences' (CSTL) Overweight Rating Reaffirmed at StephensStephens reaffirmed an "overweight" rating and set a $41.00 target price on shares of Castle Biosciences in a research report on Thursday.January 2, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by AnalystsCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objectiDecember 28, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. grew its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 87.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,382 shares of the company's stock after purchasingDecember 27, 2024 | marketbeat.comState Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)State Street Corp raised its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 9.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 680,001 shares of the company's stock after purchasing an additional 60,924 shares during the perioDecember 24, 2024 | marketbeat.comCastle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile TestDecember 23, 2024 | finance.yahoo.comPrincipal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,538,520 shares of the company's stock after purchasing an additional 40,377 shares duringDecember 23, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $265,375.76 in StockDecember 20, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the transaction, the insider now directly owns 84,762 shares in the company, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.December 19, 2024 | marketbeat.comShort Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6%Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 7.6% from the November 15th total of 1,710,000 shares. Based on an average trading volume of 390,900 shares, the days-to-cover ratio is currently 4.7 days.December 17, 2024 | marketbeat.comIndependent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to ...December 12, 2024 | businesswire.comCharles Schwab Investment Management Inc. Purchases 39,417 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Charles Schwab Investment Management Inc. boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 16.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 274,761 shares of the company'sDecember 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 1,972 SharesDecember 10, 2024 | insidertrades.comPoint72 Asset Management L.P. Purchases 445,415 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Point72 Asset Management L.P. increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 828.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 499,192 shares of the company's stock after bDecember 7, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 496,521 shares of the comDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Raises Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Parkman Healthcare Partners LLC increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 6.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 296,071 shares of the company's stock after acquiring aDecember 4, 2024 | marketbeat.comCastle Biosciences Inc.December 3, 2024 | wsj.comBellevue Group AG Grows Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Bellevue Group AG raised its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,262,030 shares of the company's stocDecember 1, 2024 | marketbeat.comBraidwell LP Has $9.47 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Braidwell LP reduced its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 20.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,986 shares of the company's stock after selling 84,114 shares duringNovember 29, 2024 | marketbeat.com43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Dynamic Technology Lab Private LtdDynamic Technology Lab Private Ltd bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 43,894 shares of the company's stock, vaNovember 27, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Connor Clark & Lunn Investment Management Ltd. raised its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 147.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,458 shares of the company'sNovember 24, 2024 | marketbeat.comCastle Biosciences to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | finance.yahoo.comFrank Stokes Sells 6,923 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockNovember 20, 2024 | insidertrades.comCastle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive YearNovember 19, 2024 | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingNovember 15, 2024 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,972 Shares of StockNovember 15, 2024 | insidertrades.comGSA Capital Partners LLP Takes Position in Castle Biosciences, Inc. (NASDAQ:CSTL)GSA Capital Partners LLP acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,827 shares of the company'sNovember 14, 2024 | marketbeat.comCastle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings SuggestNovember 12, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLCLisanti Capital Growth LLC lifted its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 154,710 shares of the company's stock after buying an additNovember 11, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,538,520 shares of the companyNovember 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $124,708.92 in StockNovember 8, 2024 | insidertrades.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.540.44▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼35▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Concentra Group Holdings Parent News Privia Health Group News Surgery Partners News Addus HomeCare News PACS Group News Ardent Health Partners News GeneDx News Progyny News Fortrea News Teladoc Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSTL Stock Alerts